Evidence map›Paper›PMID 39086467›Full record

ArticleOpen forum infectious diseases2024

Baseline C-reactive Protein as a Risk Factor for Cryptococcal Meningitis and Death in HIV-associated Cryptococcal Antigenemia With CrAg Titer as an Effect Modifier.

Caleb P Skipper, Paul Kirumira, Biyue Dai, Abduljewad Wele, Rose Naluyima, Teopista Namuli, Fred Turya, Patrick Muhumuza, Freddie Kibengo, David R Boulware and 3 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Caleb P SkipperInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.ORCID https://orcid.org/0000-0002-0000-8876
Paul KirumiraInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Biyue DaiDivision of Biostatistics & Health Data Science, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
Abduljewad WeleDivision of Biostatistics & Health Data Science, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
Rose NaluyimaInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Teopista NamuliInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Fred TuryaInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Patrick MuhumuzaMasaka Field Station, Medical Research Council/Uganda Virus Institute & London School of Hygiene and Tropical Medicine Uganda Research Unit, Masaka, Uganda.
Freddie KibengoMasaka Field Station, Medical Research Council/Uganda Virus Institute & London School of Hygiene and Tropical Medicine Uganda Research Unit, Masaka, Uganda.
David R BoulwareDivision of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
David B MeyaInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Elizabeth NalintyaInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Radha RajasinghamDivision of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0001-5531-0231

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
Operational Research for Cryptococcal Antigen Screening (ORCAS) of HIV PatientsU01AI125003 · NIAID · UNIVERSITY OF MINNESOTA · PI BOULWARE, DAVID R, MEYA, DAVID BISAGAYA · 2016 to 2020
$3.4M
Enhanced Antifungal Therapy to Improve Survival in Early Disseminated Cryptococcal InfectionU01AI174978 · NIAID · UNIVERSITY OF MINNESOTA · PI Radha Rajasingham · 2023 to 2026
$2.6M
Identifying CMV Retinitis as a Reversible Cause of Vision Loss in Persons with HIV-associated MeningitisR21EY035567 · NEI · UNIVERSITY OF MINNESOTA · PI ARUNGA, SIMON, SKIPPER, CALEB P · 2023 to 2023
$316k
NCATS NIH HHS UL1 TR002494NEI NIH HHS R21 EY035567NIAID NIH HHS U01 AI125003NIAID NIH HHS U01 AI174978
6 · The paper itself

Abstract

Background: Persons with HIV and cryptococcal antigenemia are at high risk of progression to cryptococcal meningitis or death. Baseline cryptococcal antigen (CrAg) plasma titer ≥1:160 is a known risk factor for poor outcomes, but other risk factors are unknown. In HIV-associated cryptococcal meningitis, baseline serum C-reactive protein (CRP) concentrations are positively associated with increased mortality. We hypothesized that CRP might also be associated with meningitis or death in persons with cryptococcal antigenemia. Methods: We measured plasma CrAg titers and CRP concentrations on cryopreserved serum from prospectively enrolled persons with HIV and cryptococcal antigenemia. Using time-to-event analyses, we compared 24-week meningitis-free survival in persons with normal CRP (<8 mg/L) and elevated CRP (≥8 mg/L). Logistic regression was used to assess how CRP concentration and CrAg titer might interact as covariates. Results: Of the 94 persons with elevated CRP, 19 (20.2%) developed meningitis or death, whereas of the 88 persons with normal CRP, 8 (9.1%) developed meningitis or death ( Conclusions: Our findings demonstrate that CrAg titer may modify the direction of effect of CRP with meningitis-free survival; future studies should account for this interaction.

Indexed as

c-reactive proteincryptococcal antigenemiacryptococcal antigen titerscryptococcal meningitisHIV

Identifiers

PMID39086467
PMCPMC11288378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.